Entering an Era of Radiogenomics in Prostate Cancer Risk Stratification

Overview

Journal Transl Androl Urol

Date 2018 Oct 27

PMID 30363524

Citations 4

Authors

Nachiketh Soodana-Prakash

Radka Stoyanova

Abhishek Bhat

Maria C Velasquez

Omer E Kineish

Alan Pollack

Dipen J Parekh

Sanoj Punnen

Affiliations

Soon will be listed here.

Abstract

Radiogenomics is a field that amalgamates data from genomics and imaging techniques in order to derive clinically meaningful trends. In this article, we discuss the importance of prostate cancer risk classification and how data derived from genomic testing and multi-parametric magnetic resonance imaging (mpMRI) can be integrated into clinical decision-making processes with a focus on active surveillance (AS). Finally, we describe an ongoing prospective trial (Miami MAST trial) which incorporates imaging (mpMRI) and radiomics data in patients who are on AS for prostate cancer.

Citing Articles

Quantitative diffusion MRI in prostate cancer: Image quality, what we can measure and how it improves clinical assessment.

Fennessy F, Maier S Eur J Radiol. 2023; 167:111066.

PMID: 37651828 PMC: 10623580. DOI: 10.1016/j.ejrad.2023.111066.

Radiomics vs radiologist in prostate cancer. Results from a systematic review.

Chiacchio G, Castellani D, Nedbal C, De Stefano V, Brocca C, Tramanzoli P World J Urol. 2023; 41(3):709-724.

PMID: 36867239 DOI: 10.1007/s00345-023-04305-2.

Radiogenomics influence on the future of prostate cancer risk stratification.

Banerjee V, Wang S, Drescher M, Russell R, Siddiqui M Ther Adv Urol. 2022; 14:17562872221125317.

PMID: 36160762 PMC: 9490455. DOI: 10.1177/17562872221125317.

Machine Learning: Applications and Advanced Progresses of Radiomics in Endocrine Neoplasms.

Wang Y, Zhang L, Qi L, Yi X, Li M, Zhou M J Oncol. 2021; 2021:8615450.

PMID: 34671399 PMC: 8523238. DOI: 10.1155/2021/8615450.

References

Cooperberg M, Simko J, Cowan J, Reid J, Djalilvand A, Bhatnagar S . Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013; 31(11):1428-34. DOI: 10.1200/JCO.2012.46.4396. View

Diehn M, Nardini C, Wang D, McGovern S, Jayaraman M, Liang Y . Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A. 2008; 105(13):5213-8. PMC: 2278224. DOI: 10.1073/pnas.0801279105. View

Cuzick J, Swanson G, Fisher G, Brothman A, Berney D, Reid J . Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011; 12(3):245-55. PMC: 3091030. DOI: 10.1016/S1470-2045(10)70295-3. View

Barrett T, Turkbey B, Choyke P . PI-RADS version 2: what you need to know. Clin Radiol. 2015; 70(11):1165-76. PMC: 6369533. DOI: 10.1016/j.crad.2015.06.093. View

Velasquez M, Prakash N, Venkatramani V, Nahar B, Punnen S . Imaging for the selection and monitoring of men on active surveillance for prostate cancer. Transl Androl Urol. 2018; 7(2):228-235. PMC: 5911538. DOI: 10.21037/tau.2017.08.13. View

Cuzick J, Berney D, Fisher G, Mesher D, Moller H, Reid J . Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer. 2012; 106(6):1095-9. PMC: 3304411. DOI: 10.1038/bjc.2012.39. View

Gillies R, Kinahan P, Hricak H . Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2015; 278(2):563-77. PMC: 4734157. DOI: 10.1148/radiol.2015151169. View

DallEra M, Albertsen P, Bangma C, Carroll P, Carter H, Cooperberg M . Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012; 62(6):976-83. DOI: 10.1016/j.eururo.2012.05.072. View

Siddiqui M, Rais-Bahrami S, Turkbey B, George A, Rothwax J, Shakir N . Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015; 313(4):390-7. PMC: 4572575. DOI: 10.1001/jama.2014.17942. View

10.

Yamamoto T, Musunuru H, Vesprini D, Zhang L, Ghanem G, Loblaw A . Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance. J Urol. 2015; 195(5):1409-1414. DOI: 10.1016/j.juro.2015.11.075. View

11.

Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P . Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden. JAMA Oncol. 2016; 3(10):1393-1398. PMC: 5559339. DOI: 10.1001/jamaoncol.2016.3600. View

12.

Stoyanova R, Takhar M, Tschudi Y, Ford J, Solorzano G, Erho N . Prostate cancer radiomics and the promise of radiogenomics. Transl Cancer Res. 2017; 5(4):432-447. PMC: 5703221. DOI: 10.21037/tcr.2016.06.20. View

13.

Wilt T, Jones K, Barry M, Andriole G, Culkin D, Wheeler T . Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017; 377(2):132-142. DOI: 10.1056/NEJMoa1615869. View

14.

Klein E, Haddad Z, Yousefi K, Lam L, Wang Q, Choeurng V . Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. Urology. 2016; 90:148-52. DOI: 10.1016/j.urology.2016.01.012. View

15.

Cooperberg M, Davicioni E, Crisan A, Jenkins R, Ghadessi M, Karnes R . Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol. 2014; 67(2):326-33. PMC: 4282620. DOI: 10.1016/j.eururo.2014.05.039. View

16.

Ahmed H, El-Shater Bosaily A, Brown L, Gabe R, Kaplan R, Parmar M . Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017; 389(10071):815-822. DOI: 10.1016/S0140-6736(16)32401-1. View

17.

Klein E, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson A . A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol. 2014; 67(4):778-86. DOI: 10.1016/j.eururo.2014.10.036. View

18.

Moldovan P, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh R . What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol. 2017; 72(2):250-266. DOI: 10.1016/j.eururo.2017.02.026. View

19.

Nahar B, Katims A, Barboza M, Prakash N, Venkatramani V, Kava B . Reclassification Rates of Patients Eligible for Active Surveillance After the Addition of Magnetic Resonance Imaging-Ultrasound Fusion Biopsy: An Analysis of 7 Widely Used Eligibility Criteria. Urology. 2017; 110:134-139. DOI: 10.1016/j.urology.2017.08.016. View

20.

Futterer J, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A . Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. Eur Urol. 2015; 68(6):1045-53. DOI: 10.1016/j.eururo.2015.01.013. View